Cipher Pharmaceuticals Inc. (TSE:CPH – Free Report) (NASDAQ:CPHR) – Equities researchers at Stifel Canada lowered their Q3 2024 EPS estimates for Cipher Pharmaceuticals in a report issued on Tuesday, October 22nd. Stifel Canada analyst J. Keywood now anticipates that the company will post earnings per share of $0.03 for the quarter, down from their prior estimate of $0.27. Stifel Canada has a “Strong-Buy” rating on the stock. The consensus estimate for Cipher Pharmaceuticals’ current full-year earnings is $1.65 per share. Stifel Canada also issued estimates for Cipher Pharmaceuticals’ FY2024 earnings at $0.72 EPS.
Cipher Pharmaceuticals (TSE:CPH – Get Free Report) (NASDAQ:CPHR) last released its quarterly earnings data on Thursday, August 8th. The company reported C$0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of C$0.15 by C$0.01. The company had revenue of C$7.26 million during the quarter, compared to the consensus estimate of C$7.52 million. Cipher Pharmaceuticals had a net margin of 102.01% and a return on equity of 28.43%.
Get Our Latest Stock Analysis on Cipher Pharmaceuticals
Cipher Pharmaceuticals Stock Up 2.3 %
Shares of TSE CPH opened at C$16.52 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.67 and a current ratio of 11.18. Cipher Pharmaceuticals has a 1 year low of C$4.30 and a 1 year high of C$19.69. The stock’s 50-day simple moving average is C$16.45 and its 200-day simple moving average is C$11.77. The firm has a market cap of C$422.75 million, a price-to-earnings ratio of 13.32 and a beta of 1.20.
About Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.
Further Reading
- Five stocks we like better than Cipher Pharmaceuticals
- How Technical Indicators Can Help You Find Oversold StocksĀ
- Texas Roadhouse Stock Steering for New Highs This Year
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- What is a Low P/E Ratio and What Does it Tell Investors?
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.